Trial Profile
A Phase III Randomized, Double-Blind, Placebo Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Dec 2021
Price :
$35
*
At a glance
- Drugs Phentermine/topiramate (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Acronyms CONQUER
- 28 Apr 2017 Results (n=3040) assessing efficacy and safety of phentermine/topiramate extended release for weight loss in overweight and obese patients using pooled data from CONQUER, EQUIP and SEQUEL trials, published in the Diabetes Care
- 24 Feb 2015 Results were presented as per Vivus Inc. media release.
- 26 Jun 2012 Results from a post-hoc analysis presented at the 94th Annual Meeting of the Endocrine Society.